Overview Of Value Stocks In The Basic Materials Sector

What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the…

What Defines a Value Stock?

A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

Benzinga Insights has compiled a list of value stocks in the basic materials sector that may be worth watching:

  1. Teck Resources (NYSE:TECK) – P/E: 7.68
  2. Sociedad Quimica Y Minera (NYSE:SQM) – P/E: 5.24
  3. Alpha Metallurgical (NYSE:AMR) – P/E: 2.17
  4. Warrior Met Coal (NYSE:HCC) – P/E: 2.9
  5. Valhi (NYSE:VHI) – P/E: 9.39

Teck Resources has reported Q1 earnings per share at $1.32, which has increased by 65.0% compared to Q4, which was 0.8. Sociedad Quimica Y Minera saw a decrease in earnings per share from 4.03 in Q4 to $2.63 now. Most recently, the company reported a dividend yield of 12.69%, which has increased by 4.48% from last quarter’s yield of 8.21%.

Alpha Metallurgical has reported Q1 earnings per share at $17.01, which has increased by 27.23% compared to Q4, which was 13.37. Most recently, the company reported a dividend yield of 1.42%, which has increased by 0.38% from last quarter’s yield of 1.04%.

Most recently, Warrior Met Coal reported earnings per share at $3.57, whereas in Q4 earnings per share sat at $1.9. Valhi’s earnings per share for Q1 sits at $-0.17, whereas in Q4, they were at -0.33. Its most recent dividend yield is at 2.35%, which has increased by 1.05% from 1.3% in the previous quarter.

The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

Total
0
Shares
Related Posts
Read More

AstraZeneca Announced Enhertu Granted Priority Review in the US for Patients with HER2-low Metastatic Breast Cancer

AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application (sBLA) of Enhertu (trastuzumab deruxtecan) for the treatment of adult patients in the US with unresectable or metastatic HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in-situ hybridisation [ISH]-negative) breast cancer who have received a prior therapy in the metastatic set

AZN